Summary
Purpose This phase I study was performed to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of an untargeted liposomal formulation of vinorelbine (NanoVNB®) and to characterize its plasma pharmacokinetics in patients with advanced solid tumors which were refractory to conventional treatment or without an effective treatment. Patients & methods The study incorporated an accelerated titration design. Twenty-two patients with various solid tumors were enrolled. NanoVNB® was administered intravenously at doses of 2.2–23 mg/m2 once every 14 days. Pharmacokinetic endpoints were evaluated in the first cycle. The safety profiles and anti-tumor effects of NanoVNB® were also determined. Results Skin rash was the DLT and the most common non-hematological toxicity. The MTD was 18.5 mg/m2. Drug-related grade 3–4 hematological toxicities were infrequent. Compared with intravenous free vinorelbine, NanoVNB® showed a high Cmax and low plasma clearance. Of the 11 patients completing at least 1 post-treatment tumor assessment, 5 had stable disease. No responders were noted. Conclusion NanoVNB® was well tolerated and exhibited more favorable pharmacokinetic profiles than free vinorelbine. Based on dose-limiting skin toxicity, further evaluation of NanoVNB® starting from 18.5 mg/m2 as a single agent or in combination with other chemotherapeutic agents for vinorelbine-active malignancies is warranted.
Similar content being viewed by others
References
Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P (1979) 5′-Noranhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 35:2175–2179
Mangeney P, Andriamialisoa RZ, Langlois N, Langlois Y, Potier P (1979) A new class of antitumor compounds: 5′-nor and 5′, 6′-seco derivatives of vinblastine-type alkaloids. J Org Chem 44:3765–3768
Maral R, Bourut C, Chenu E, Mathé G (1981) Experimental in vivo cross-resistance of vinca alkaloid drugs. Cancer Chemother Pharmacol 5:197–199
Maral R, Bourut C, Chenu E, Mathé G (1984) Experimental antitumor activity of 5′-nor-anhydrovinblastine navelbine. Cancer Lett 22:49–54
Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC (1991) A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14:115–119
Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245–1252
Gebbia V, Testa A, Valenza R et al (1993) A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29:1358–1359
Conroy T, Etienne PL, Adenis A et al (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 14:164–170
Bajetta E, Di Leo A, Biganzoli L et al (1996) Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 14:2546–2551
Lacava JA, Leone BA, Machiavelli M et al (1997) Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 15:604–609
Nasti G, Errante D, Talamini R et al (2000) Vinorelbine is an effective and safe drug for AIDS-related Kaposi’s sarcoma: results of a phase II study. J Clin Oncol 18:1550–1557
Sharpe M, Easthope SE, Keating GM, Lamb HM (2002) Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi’s sarcoma. Drugs 62:2089–2126
Drummond DC, Noble CO, Guo Z et al (2009) Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J Pharmacol Exp Ther 328:321–330
Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743
Allen TM (1997) Liposomes. Opportunities in drug delivery. Drugs 54(Suppl 4):8–14
Treat J, Greenspan A, Forst D et al (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 82:1706–1710
Pestalozzi B, Schwendener R, Sauter C (1992) Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3:445–449
Gelmon KA, Tolcher A, Diab AR et al (1999) Phase I study of liposomal vincristine. J Clin Oncol 17:697–705
Rosenthal DI, Yom SS, Liu L et al (2002) A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 20:343–349
Kehrer DF, Bos AM, Verweij J et al (2002) Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 20:1222–1231
Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160
Khayat D, Rixe O, Brunet R et al (2004) Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Cancer Chemother Pharmacol 54:193–205
Medical Economics Staff (2003) Physicians’ desk reference, 57th ed. Medical Economics
Semple SC, Leone R, Wang J et al (2005) Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci 94:1024–1038
Zhigaltsev IV, Maurer N, Akhong QF et al (2005) Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 104:103–111
Webb MS, Johnstone S, Morris TJ et al (2007) In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm 65:289–299
Liu Y, Lu WL, Guo J et al (2008) A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 129:18–25
Lotem M, Hubert A, Lyass O et al (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136:1475–1480
Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T (1997) Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 24:337–344
Acknowledgments
This work was supported by Taiwan Liposome Co., Ltd. (Taipei, Taiwan).
Conflict of interest statement
No financial or other potential conflicts of interest exist for any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, SH., Lin, CC., Lin, ZZ. et al. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Invest New Drugs 30, 282–289 (2012). https://doi.org/10.1007/s10637-010-9522-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9522-3